Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
guided radiotherapy · 1 trial · 1 indication
The total number of planned radiotherapy fractions that are administered, without clinically unacceptable interruptions, on the Alberta linac-MR P3 system. The study will track the number of planned fractions administered per participant without any significant interruptions or delays in their treatment.
| Arm | Type | Description |
|---|---|---|
| MR guided radiotherapy | EXPERIMENTAL | MR-guided radiotherapy using the Alberta linac-MR P3 system. Contemporary radiotherapy techniques and fractionation schedules will be conducted in the following graduated stages with overlap between stages allowed: Stage 1: Parallel-opposed pair treatments (palliative) Stage 2: 4 field box treatments (curative or palliative) Stage 3: High dose treatments - multi-field 3DCRT (curative or palliative) Stage 4: High dose treatments - multi-field IMRT (curative or palliative) |
| Name | Type | Description |
|---|---|---|
| MR guided radiotherapy | DEVICE | MR guided radiotherapy using the Alberta linac-MR P3 system |
Inclusion Criteria: * Adults ≥ 18 years of age * Patients deemed fit to undergo external beam radiation therapy by their attending radiation oncologist * Accessible for follow-up Exclusion Criteria: * Patients with contraindications for MRI * Patients who are unable to lie flat and still for the ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Guided radiotherapy is an investigational treatment approach being studied for use in cancer. It is currently in Phase 1 clinical development, meaning it is being evaluated for safety and feasibility in patients. The therapy is not yet approved and remains under investigation through an active clinical trial.
Guided radiotherapy is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company is conducting clinical research on this investigational cancer treatment. Avalon GloboCare Corp. is publicly traded under the ticker symbol ALBT.
Guided radiotherapy is currently in Phase 1 clinical development. This early-stage trial is designed to assess the safety and feasibility of the treatment approach in cancer patients. The study is actively recruiting participants, and the therapy remains investigational, meaning it has not yet received regulatory approval.
Guided radiotherapy is being evaluated in one active clinical trial, identified as NCT05413473, titled "Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)." This Phase 1 study is recruiting 99 adult participants with cancer in Canada. The trial is uncontrolled and not randomized or blinded.
Guided radiotherapy is not FDA approved. It is an investigational treatment currently in Phase 1 clinical development for cancer. The therapy is being studied in an active clinical trial to evaluate its safety and feasibility, but it has not yet completed the clinical development process required for regulatory approval.